Limits...
Serum SALL4 is a novel prognosis biomarker with tumor recurrence and poor survival of patients in hepatocellular carcinoma.

Han SX, Wang JL, Guo XJ, He CC, Ying X, Ma JL, Zhang YY, Zhao Q, Zhu Q - J Immunol Res (2014)

Bottom Line: Sal-like protein 4 (SALL4), is reexpressed in tissues of a subgroup of HCC associated with poor prognosis.HCC patients displayed higher levels (50.4%) of SALL4 protein in serum, compared with the three control groups.High SALL4 serum levels are a novel biomarker in the prognosis of HCC patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University Medical College, Xi'an, Shaanxi 710061, China.

ABSTRACT

Aim: Sal-like protein 4 (SALL4), is reexpressed in tissues of a subgroup of HCC associated with poor prognosis. Reports of SALL4 serological levels linked to HCC patients are meager and unclear in the prognosis of this malignancy.

Methods: Immunohistochemistry and optical microscopy protocols were used to examine the presence of SALL4 in liver tissues from the following patients: 38 HCC, 11 chronic hepatitis B virus (HBV), 13 liver cirrhosis, and 12 healthy controls. Additionally, enzyme-linked immunosorbent assay (ELISA) was used to measure the SALL4 levels in serum samples isolated from patients as follows: 127 with HCC, 27 with HBV, 24 with liver cirrhosis, and 23 normal controls.

Results: Analysis of liver tissues sections from HCC patients (18 out 38; 47.4%) showed positive staining for SALL4 and its expression did no correlate with any of the clinicopathologic characteristics. HCC patients displayed higher levels (50.4%) of SALL4 protein in serum, compared with the three control groups. Moreover, SALL4 concentration reached the maximum level after one week after treatment and dropped quickly after one month. These HCC patients showing high SALL4 serum levels had poor prognosis, evidenced by both tumor recurrence and overall survival rate.

Conclusions: High SALL4 serum levels are a novel biomarker in the prognosis of HCC patients.

Show MeSH

Related in: MedlinePlus

Kaplan-Meier curves showed a lower rate of overall survival in HCC patients with high expression of serum SALL4 than with low expression of serum SALL4.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4016881&req=5

fig3: Kaplan-Meier curves showed a lower rate of overall survival in HCC patients with high expression of serum SALL4 than with low expression of serum SALL4.

Mentions: Furthermore, we carried out overall survival analysis (Kaplan-Meier analysis) for these 56 HCC patients. The analysis showed HCC patients with high SALL4 serum levels had worse prognosis than patients with low serum SALL4 expression (P = 0.013) (as shown in Figure 3), which means HCC patients with low serum concentration of SALL4 protein had a better prognosis. The median survival of patients with SALL4 low serum levels was of 536 days, whereas the median survival of patients with high SALL4 serum levels was only 375 days (P = 0.023).


Serum SALL4 is a novel prognosis biomarker with tumor recurrence and poor survival of patients in hepatocellular carcinoma.

Han SX, Wang JL, Guo XJ, He CC, Ying X, Ma JL, Zhang YY, Zhao Q, Zhu Q - J Immunol Res (2014)

Kaplan-Meier curves showed a lower rate of overall survival in HCC patients with high expression of serum SALL4 than with low expression of serum SALL4.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4016881&req=5

fig3: Kaplan-Meier curves showed a lower rate of overall survival in HCC patients with high expression of serum SALL4 than with low expression of serum SALL4.
Mentions: Furthermore, we carried out overall survival analysis (Kaplan-Meier analysis) for these 56 HCC patients. The analysis showed HCC patients with high SALL4 serum levels had worse prognosis than patients with low serum SALL4 expression (P = 0.013) (as shown in Figure 3), which means HCC patients with low serum concentration of SALL4 protein had a better prognosis. The median survival of patients with SALL4 low serum levels was of 536 days, whereas the median survival of patients with high SALL4 serum levels was only 375 days (P = 0.023).

Bottom Line: Sal-like protein 4 (SALL4), is reexpressed in tissues of a subgroup of HCC associated with poor prognosis.HCC patients displayed higher levels (50.4%) of SALL4 protein in serum, compared with the three control groups.High SALL4 serum levels are a novel biomarker in the prognosis of HCC patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University Medical College, Xi'an, Shaanxi 710061, China.

ABSTRACT

Aim: Sal-like protein 4 (SALL4), is reexpressed in tissues of a subgroup of HCC associated with poor prognosis. Reports of SALL4 serological levels linked to HCC patients are meager and unclear in the prognosis of this malignancy.

Methods: Immunohistochemistry and optical microscopy protocols were used to examine the presence of SALL4 in liver tissues from the following patients: 38 HCC, 11 chronic hepatitis B virus (HBV), 13 liver cirrhosis, and 12 healthy controls. Additionally, enzyme-linked immunosorbent assay (ELISA) was used to measure the SALL4 levels in serum samples isolated from patients as follows: 127 with HCC, 27 with HBV, 24 with liver cirrhosis, and 23 normal controls.

Results: Analysis of liver tissues sections from HCC patients (18 out 38; 47.4%) showed positive staining for SALL4 and its expression did no correlate with any of the clinicopathologic characteristics. HCC patients displayed higher levels (50.4%) of SALL4 protein in serum, compared with the three control groups. Moreover, SALL4 concentration reached the maximum level after one week after treatment and dropped quickly after one month. These HCC patients showing high SALL4 serum levels had poor prognosis, evidenced by both tumor recurrence and overall survival rate.

Conclusions: High SALL4 serum levels are a novel biomarker in the prognosis of HCC patients.

Show MeSH
Related in: MedlinePlus